Parabilis Medicines, Inc.
A complete Wall Street Score is unavailable because required model components are missing. Missing model components: asset-model component, revenue, moat, financial, Buffett-style model component. These are scoring components, not a claim that the company has no assets or earnings. Missing inputs are not zero and do not by themselves make this a weak company. Available financial statements and source-backed research remain visible.
PBLS · Price history
Price at last available close
$26.51
−$6.06 (-18.61%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Parabilis Medicines, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L.
How they make money
Parabilis Medicines is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel therapeutic candidates, specifically stabilized helical peptides known as Helicons, which are designed to modulate historically undruggable protein targets. The company relies on external financing, such as venture capital and public offerings, to fund its ongoing clinical trials and operational expenses.
Products & services
The company's primary product candidate is zolucatetide (FOG-001), a first-in-class therapy targeting the Wnt/beta-catenin pathway for the treatment of various cancers, including desmoid tumors.
Brands & revenue mix
Proprietary platform for stabilized helical peptides.
Separate brand revenue is not available in this research.Source
Lead clinical-stage therapeutic candidate.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials.Source
Competitors
- Pharmaceutical and Biotechnology Companies — The company competes with various established pharmaceutical and biotechnology companies that are developing therapies for cancer and other diseases using different or similar therapeutic modalities.Source
Strengths
Sources
Company-specific research
Questions worth answering for PBLS
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can PBLS fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is PBLS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for PBLS to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PBLS's current valuation?
- •What does the current share basis reconciled warning mean for the reliability or interpretation of PBLS's score?
Essential Investment Snapshot
Market Cap
$3.23B
P/E Ratio
-0.5
EPS
$-61.10
52-Week High
$42.49
52-Week Low
$20.00
Beta
5.03
Analyst Target
$40.00
Shares Outstanding
116.6M
Total Debt
$47.5M
Dividend
No current dividend
Liquidation Value / Share
$8.99
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for PBLS
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-99.9x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on PBLS.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary Helicon peptide platform technology.
- +Experienced leadership team in drug development.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on the success of a single lead product candidate, zolucatetide.
- −Risks associated with clinical trial development and regulatory approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$26.51
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | $148K | $0.00 | $0.00 |
| Cost of Revenue | $618K | $0.00 | $0.00 |
| Gross Profit | -$470K | $0.00 | $0.00 |
| Research & Development | $141.2M | $125.6M | $100.8M |
| SG&A Expenses | $33.5M | $26.5M | $25.3M |
| Operating Expenses | $174.6M | $152.1M | $126.1M |
| EBITDA | -$169.3M | -$141.9M | -$114.3M |
| Operating Income | -$175.1M | -$152.1M | -$126.1M |
| Interest Expense | $1.3M | $1.5M | $1.5M |
| Income Before Tax | -$170.9M | -$145.9M | -$117.9M |
| Income Tax Expense | $0.00 | $0.00 | $0.00 |
| Net Income | -$170.9M | -$145.9M | -$117.9M |
| Basic EPS | $-61.10 | $-92.40 | $-83.48 |
| Basic Shares | 28.91M | 2.02M | 1.93M |
| Diluted Shares | 28.91M | 2.02M | 1.93M |
Earnings Summary
Revenue
$148000
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$2.32
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
No material change
Cash Change
No material change
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Potential Score Impact
Positive indicators included EPS growth. Pressure indicators included cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 544.4%. Cash was essentially unchanged. Total debt was essentially unchanged.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
Rumor Mill · PBLS
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial